Lupin, Inc.

Lupin Atlantis Holdings Sa

4sc Ag

Sanjeev Anant Kulkarni

Venkata Poornapragnacharyulu Palle

Rajender Kumar Kamboj

Manojkumar Ramprasad Shukla

Mahadeo Bhaskar Tryambake

Ankush Gangaram Sarde

Chetan Sanjay Pawar

Navnath Bajirao Walke

Thomas Maier

Astrid Zimmermann

Volker Gekeler

Prathap Sreedharan Nair

Talha Hussain Khan

Chaitanya Prabhakar Kulkarni

Rajeshkumar Maganlal Loriya

Ganesh Bhausaheb Gudade

Dipak Raychand Lagad

Anil P Jagtap

Ganesh S Chaure

Vinod Dinkar Chaudhari

Ramesh Dattatraya Phadtare

Vipul Dilip Pachpute

Hans-Peter Hofmann

Milind Dattatraya Sindkhedkar

Anil Kashiram Hajare

Sachin Sethi

Majid Bashir Sayyed

Balasaheb Arjun Gore

Nirmal Kumar Jana

Sachin Jaysing Mahangare

Dronamraju Prameela

Prashant Popatrao Vidhate

Ganesh Navinchandra Gote

Prashant Vitthalrao Tale

Narasimha Murthy Cheemala

Sapana Suresh Patel

Amolsing Dattu Patil

Seema Prabhakar Zade

Rohan Mahadev Shinde

Sarde Gangaram Ankush

Pachpute Dilip Vipul

Anand Jagannath Tarage

Sachin Madan

Venkata P Palle

The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors

The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. 

Substituted chroman compounds as calcium sensing receptor modulators

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R-R, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject. 

Quinolizinone derivatives as PI3K inhibitors

Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.

Substituted imidazoquinolines

The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. (Formula I) 

Arylalkylamine compounds as calcium sensing receptor modulators

The invention relates to naphthalene compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium sensing receptor modulators (Ca SR). The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium sensing receptor modulators (Ca SR) channel modulators.

Substituted naphthalene compounds as calcium sensing receptor modulators

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors of Formula (I). 

Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators

Substituted morpholines as modulators for the calcium sensing receptor

The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. 

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I). 

Cannabinoid receptor modulators

Growing community of inventors

Pune, India

Sanjeev Anant Kulkarni